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Avian inﬂuenza A viruses continue to cause disease outbreaks in humans, and extrapulmonary infection is
characteristic. In vitro studies demonstrate the activity of oseltamivir against avian viruses of the H5, H7 and
H9 subtypes. In animal models of lethal infection, oseltamivir treatment and prophylaxis limit viral replication
and improve survival. Outcomes are inﬂuenced by the virulence of the viral strain, dosage regimen and treat-
ment delay; it is also critical for the compound to act systemically. Observational data on oseltamivir treatment
in the early stages of disease suggest it is useful for improving survival in patients infected with H5 viruses, and
drug-selected resistance has only rarely been reported. The WHO strongly recommends oseltamivir for the
treatment of conﬁrmed or suspected cases of human H5 infection and prophylaxis of those at high risk of infec-
tion. In addition to oral dosing, nasogastric administration appears to be a viable option for the management of
severely ill patients, as is the use of higher doses and prolonged schedules. F. Hoffmann-La Roche Ltd, the man-
ufacturer of oseltamivir, is developing a mathematical model to allow rapid prediction of appropriate dosage
regimens for any future pandemic. Roche is also funding the Avian Inﬂuenza Registry, an online database
that aims to collect information from clinicians worldwide on the course of avian inﬂuenza in humans.
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Introduction
Inﬂuenza A viruses cause recurrent epidemics with substantial
human morbidity and mortality, and are also associated with
pandemics.
1 As pandemic inﬂuenza A has its origins in avian
inﬂuenza viruses, the highly pathogenic H5N1 viruses that have
become panzootic in domestic and wild fowl have to be con-
sidered a serious threat.
1–3H5N1 is principally a zoonosis, with
transmission in the ﬁrst instance typically from fowl, or fowl
product, to humans, although the primary source of exposure
cannot always be determined.
4 Recent evidence supports the
occurrence of limited human to human transmission,
4–9 while
evidence from Pakistan supports human to human to human
(third-generation) transmission.
8
The typical clinical manifestation of H5 infection is inﬂuenza-
like illness, with the development of dyspnoea and progression to
severe illness, usually typiﬁed by fulminant pneumonia compli-
cated by acute respiratory distress syndrome (ARDS); multiorgan
failure and death may follow.
2,10,11 Gastrointestinal disturbances
may also be evident, and the illness may present as a
gastroenteritis-like condition.
12 Neurological signs and symp-
toms have also been reported.
13,14 Cases of mild illness and
asymptomatic infection are evident,
4,15–18 but the extent of
these less dramatic infections remains largely unknown.
Common laboratory ﬁndings of abnormality include leucope-
nia, lymphopenia and thrombocytopenia.
2,11Mortality is high; up
to 31 August 2009, of 440 laboratory-conﬁrmed cases of H5N1
infection reported to the WHO since 2003, 262 (60%) were
fatal.
19 Although most cases have been reported in South-East
Asia,
19 Egypt accounts for the third greatest number of cases,
and a signiﬁcant outbreak was reported from Eastern Turkey.
18
Wild birds in a number of EU countries have tested positive for
H5, and 14 outbreaks in domestic poultry had been reported in
six member states by early December 2007.
20
Avian viruses of the H7 subtype also cause human disease
outbreaks, and appear to have a predilection for the conjunctiva,
as well as causing respiratory illness. In an outbreak in the Neth-
erlands, a H7N3 virus of avian origin was detected in 89 persons,
of whom 85 presented with conjunctivitis and/or inﬂuenza-like
illness.
21 Symptoms were generally mild, but a fatal case of
pneumonia in combination with ARDS was reported. In the UK,
three outbreaks of H7N2 disease with inﬂuenza-like illness and/
or conjunctivitis have been reported;
22–25 in one of these out-
breaks, three of the four cases documented were hospitalized.
22
Cases of H7 disease have also been reported in the USA (H7N2),
26
Canada (H7N3)
27 and Italy (H7N3).
28 In some of these out-
breaks, seroconversion was not detectable in all patients with
symptomatic disease. The reason for this is unclear, but it
seem likely that some H7 infections go undetected.
29 Sympto-
matic infections with H9N2 viruses were reported in Hong
Kong, but the illness appears to be mild.
30 Seropositivity for H9
has also been reported from China.
31
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ii25In the face of these developments, the antiviral medication
oseltamivir (Tamiﬂu
w; F. Hoffmann-La Roche Ltd) is rec-
ommended on the basis of observational data and systemic
activity by the WHO as the primary treatment for H5N1 infection,
with particular potential for reducing mortality if used in the
early stages of disease.
32,33 Oseltamivir also appears active in
the attempts to control disease outbreaks caused by H7 avian
viruses.
34,35
Treatment experience
Pre-clinical studies
H5N1 viruses isolated from infected humans have been shown to
be susceptible to oseltamivir in pre-clinical studies in vitro and in
animal models.
36–38 Two studies focused on the inﬂuenza A/HK/
156/97 (H5N1) strain that was transmitted to humans in Hong
Kong in 1997 and killed 6 of 18 people infected. Leneva et al.
38
showed that oseltamivir carboxylate inhibited replication of the
virus in Madin–Darby canine kidney (MDCK) cells with an EC50
(50% effective concentration) of 7.5+2.5 mmol/L. In this study,
mice given 1 or 10 mg/kg oseltamivir after lethal challenge
with A/HK/156/97 (H5N1) did not die and lost less weight than
controls; mice treated with 0.1 mg/kg showed improved survival.
In a similar study of the same viral strain, 90% of infected
animals survived when given 10 mg/kg/day oseltamivir for
5 days starting 24 h after lethal infection.
36 When treatment
was started 60 h after infection, 65% survived. Systemic efﬁcacy
was demonstrated by the prevention of spread of virus to the
brain by daily dosages of 1 and 10 mg/kg. Oseltamivir was also
active against the viral subtype A/quail/HK/G1/97 (H9N2) in
both of these studies.
36,38
The importance of early treatment has been shown by effects
on more recent clinical isolates successfully treated with oselta-
mivir in animals. Ferrets were protected from lethal infection with
inﬂuenza A/Vietnam/1203/04 (H5N1) by 5 mg/kg oseltamivir
daily when started 4 h after infection, but 25 mg/kg daily was
needed when treatment was started after 24 h.
37 A dosage of
10 mg/kg daily attenuated viral symptoms and blocked viral
spread to internal organs when animals were challenged with
the less pathogenic A/Turkey/15/06 strain.
The signiﬁcance of systemic action has been highlighted by
results in chickens infected with inﬂuenza A/Chicken/Pennsylvania/
1370/83 (H5N2). Chickens infected with virus were caged with
contact chickens; treated birds received either intratracheal
1 mg/kg zanamivir or oral 120 mg/kg oseltamivir twice daily
from 1 day before infection to 7 days afterwards. Monitoring
for infection was carried out daily to day 8 and then on day
14. As indicated in Figure 1, zanamivir (which is distributed to
the lungs only) had no effect on rates of infection and mortality
while oseltamivir showed beneﬁcial effects.
39
Clinical studies
Evidence pointing to the activity of oseltamivir against avian
inﬂuenza in pre-clinical studies is supported by data in humans
who have contracted H5N1. A summary of results from clinical
case series in patients who contracted clade 1 or 2 inﬂuenza A
(H5N1) viruses and who recovered after treatment with oselta-
mivir is shown in Figure 2.
2,11,40Overall, results from uncontrolled
studies suggest that survival is improved 2-fold by the use of
oseltamivir, with early therapy being recommended.
2,11,40
However, the WHO recommends that late presentation should
not preclude the initiation of oseltamivir therapy.
32
Mortality remains high despite use of oseltamivir, but delayed
initiation of treatment appears to be a key factor, as exempliﬁed
by the most recent analysis of data from Indonesia,
41 experience
in Egyptian patients
42 and pooling of results for the years
2004–06 from Vietnam, Thailand, Indonesia and Turkey.
43 Indo-
nesia has put in place surveillance and referral systems for
human H5N1 infections since February 2004, and data are avail-
able for 127 patients with conﬁrmed onset from June 2005 to
February 2008 (this includes 54 included in a previous data set
with a case fatality rate of 76%).
44 Of the 127 patients, 103
(81%) died; 88 patients were treated with oseltamivir (median
time to treatment of 7 days). Patients with early oseltamivir
treatment showed signiﬁcantly increased survival (P¼0.03 for
trend; Figure 3).
41 Pooled data from Vietnam, Thailand, Indone-
sia and Turkey show similar survival in patients treated with osel-
tamivir (13/34; 38%) and those not treated (4/16; 25%).
43
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Figure 2. Survival among H5N1-infected patients treated with
oseltamivir. Figure derived from data in WHO Writing Committee,
2 Liem
et al.
11 and Hien et al.
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Figure 1. Infection and mortality in chickens inoculated with and in
contact with inﬂuenza A/Chicken/Pennsylvania/1370/83 (H5N2); n¼5
chickens per group. ‘Infection’ refers to systemic infection indicated by
virus isolation from the cloaca (with or without tracheal infection).
Figure derived from data in Meijer et al.
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ii26However, when time to treatment was accounted for, patients
receiving oseltamivir within 5 days of onset showed 53% survival
(8/15) compared with 26% of those who received oseltamivir
 6 days after onset of disease (5/19).
To further investigate the clinical features, disease course and
impact of antiviral treatment in human H5N1 infections, Roche is
funding the AVEX Avian Inﬂuenza Registry, an online database
that aims to collect information from clinicians worldwide.
45
This will be one of the largest sources of such information avail-
able. Data from 177 patients in eight countries were available for
initial analysis as of August 2009.
45 The median age of patients
was 20 years (range: 1.25–67 years) and 49% were male. Treat-
ment with oseltamivir signiﬁcantly improved crude survival rates
for patients who received at least one dose [45/78 (58%) versus
10/87 (11%) for patients who received no antiviral; P,0.0001]. A
signiﬁcant survival beneﬁt over no antiviral treatment remained
even when oseltamivir was not initiated until days 6–8 of
illness [12/23 (52%) patients given oseltamivir surviving versus
20/101 (20%) for no antiviral; P¼0.003], but early treatment
provided the greatest impact on mortality [survival on days
1–2; 6/8 (75%) among patients treated with oseltamivir versus
45/153 (29%) untreated patients; P¼0.014].
45
Prophylaxis experience
Pre-clinical studies
Oseltamivir was effective as prevention in the murine studies of
the 1997 Hong Kong virus discussed earlier when 5 day courses
were started 4 h before potentially lethal infection with A/HK/
156/97 (H5N1); 100% survival was reported with daily dosages
 0.1 mg/kg (Table 1).
36,38
Dose-dependent effects have also been reported in prophylac-
tic studies focusing on the more recent A/Vietnam/1203/04
(H5N1) virus, originally isolated from a throat swab from a
fatallyinfected person.
46,47A 5 dayregimen of10 mg/kg/daypro-
tected50%ofmiceandincreaseddurationofsurvival(Table1);an
increase in duration of therapy to 8 days improved efﬁcacy and
conferred survival rates of up to 80%. This viral variant is more
virulent in mice than the earlier inﬂuenza subtype A/HK/156/97
(H5N1), which points to the potential need for more prolonged
therapy at higher dosages.
47 In a more recent study, 100% survi-
val was reported in ferrets protected with 10 day oseltamivir
started before infection with inﬂuenza A/Vietnam/1203/04
(H5N1) (Table 1).
46 When oseltamivir was given twice daily to
these animals, clinical signs, systemic virus distribution and
organ pathology were also prevented.
Clinical studies
There is currently only limited information available regarding the
efﬁcacy of oseltamivir for the prevention of human infection with
avian inﬂuenza virus. No clinical trial has evaluated oseltamivir
for the prevention of H5N1.
33 However, modelling of an emerging
outbreak in rural Asia has predicted the beneﬁt of mass targeted
antiviral prevention in terms of delaying or stopping spread of
disease, and the WHO already has a stockpile of oseltamivir for
this purpose.
2
Kang et al.
48 detailed an analysis of 2512 people involved in
the management of inﬂuenza A/Chicken/Korea/ES/03 (H5N1)
that caused 19 outbreaks in seven provinces in Korea in
2003–04. All those directly involved in the culling operations
were equipped with personal protective equipment, were vacci-
nated with commercial seasonal inﬂuenza vaccine and received
oseltamivir as prophylaxis. None of the persons studied devel-
oped any inﬂuenza-like symptoms or fever, although nine indi-
viduals seroconverted (0.36%), showing that they had been
directly exposed to the virus but that infection was not associ-
ated with clinical signs (see later for discussion of serconversion
data from animals and patients given oseltamivir).
An updated review by the Committee for Medicinal Products
for Human Use (CHMP) of the European Medicines Agency
(EMEA) published in December 2007 of antiviral medicinal pro-
ducts for potential use during a pandemic also noted that
‘during the 2003 avian inﬂuenza H7N7 outbreak in the Nether-
lands, oseltamivir with the recommended prophylactic dose of
75 mg once daily seemed to be effective to protect poultry
workers and their close contacts’.
34 The use of oseltamivir as
prophylaxis was also linked to a signiﬁcant reduction in the risk
of conjunctivitis (a common extrapulmonary symptom of H7N7
infection).
35 These data also support a rationale for the potential
utility of oseltamivir in avian inﬂuenza A infections of subtypes
other than H5N1. Lim et al.
49 presented a case study of an out-
break of highly pathogenic avian inﬂuenza A (H5N1) on a farm in
the UK in 2007. Information was available for 482 people con-
sidered at risk of exposure to H5N1 during the outbreak. Oselta-
mivir was provided as post-exposure prevention to 11 farm
workers exposed at the time of the outbreak, none of whom
was subsequently hospitalized or reported to have developed
clinical symptoms of H5N1 infection.
Seroconversion data
Information about the production of antibodies to avian inﬂu-
enza viruses during oseltamivir treatment is limited, but ﬁndings
to date suggest that oseltamivir does not prevent the develop-
ment of humoral immune responses to inﬂuenza A (H5N1)
that are adequate to prevent re-infection.
100
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Figure 3. Rates of recovery according to time to oseltamivir treatment in
patients infected with inﬂuenza A/H5N1 in Indonesia from June 2005 to
February 2008. Initiation of treatment within 2 days was associated with
signiﬁcantly lower mortality than initiation after 5–6 days or later
(P,0.0001). Figure derived from data in Kandun et al.
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JACAntibody production has been reported in ferrets inoculated
with H5N1 virus and subsequently treated with oseltamivir,
which supports the contention that the drug does not interfere
with serum antibody production.
37 Treated animals surviving
lethal challenge with inﬂuenza A/Vietnam/1203/04 (H5N1)
showed levels of HI antibody to inﬂuenza A/Vietnam/1203/04
(H5N1) that were low but nevertheless sufﬁcient to provide com-
plete protection against lethal rechallenge. Similar results were
reported in animals initially challenged with inﬂuenza A/Turkey/
15/06 (H5N1), although homologous HI titres were considerably
higher (Table 2). Boltz et al.
46 subsequently also reported low but
sufﬁcient homologous HI titres in treated ferrets surviving lethal
challenge with A/Vietnam/1203/04 (H5N1), with higher titres of
the heterologous virus A/HK/213/03 (H5N1). No clinical signs of
infection were seen in any ferrets undergoing lethal rechallenge
with inﬂuenza A/Vietnam/1203/04 (H5N1). Overall, these ﬁndings
are compatible with the premise that, rather than preventing
infection, prophylaxis limits the course of inﬂuenza infection
within its early stages and prior to the onset of symptomatic
disease.
Seroconversion has also been noted in humans treated with
oseltamivir for exposure to avian inﬂuenza, notably the nine indi-
viduals(seeearlier)whoseroconvertedafterexposuretoinﬂuenza
A/Chicken/Korea/ES/03 (H5N1).
48 In a retrospective studyof avian
inﬂuenza in 705 persons involved in the 2003 outbreak of H7N7
virusintheNetherlands,amodiﬁedHIassayshowedthepresence
of anti-H7 antibodies in 49% of 508 persons exposed to poultry
and64%of63personsexposedtoinfectedhumans.
35Theseﬁnd-
ings are consistent with those observed in seasonal inﬂuenza.
Dose optimization
Whereas the majority of cases of H5N1 reported to date have
been managed with the approved oseltamivir regimen of
Table 1. Effects on survival of oseltamivir as prevention started 4 h before infection with avian inﬂuenza A viruses in animal models
Reference (animal type) Virus Treatment Dosage (mg/kg) Survivors/total Mean survival (days)
Govorkova et al.
36 (mice) A/HK/156/97 (H5N1) oseltamivir  5 days 0.01 2/6 11.3
0.1 6/6 16.0
1.0 5/5 16.0
control 0/11 6.3
A/quail/HK/G1/97 (H9N2) oseltamivir  5 days 0.01 5/11 12.2
0.1 4/11 11.9
1.0 11/11 16.0
10.0 12/12 16.0
control 0/11 8.0
Leneva et al.
38 (mice) A/HK/156/97 (H5N1) oseltamivir  5 days 0.1 4/5 14.0
1.0 5/5 .16.0
10.0 5/5 .16.0
control 0/4 7.5
A/quail/HK/G1/97 (H9N2) oseltamivir  5 days 0.1 5/10 9.8
1.0 9/9 .16.0
10.0 10/10 .16.0
100.0 10/10 .16.0
control 0/10 4.0
A/HK/1074/99 (H9N2) oseltamivir  5 days 0.1 3/5 11.2
1.0 5/5 .16.0
10.0 5/5 .16.0
control 2/5 8.8
Boltz et al.
46 (ferrets) A/Vietnam/1203/04 (H5N1) oseltamivir  10 days 5 3/3
10 3/3
control 0/3
Yen et al.
47 (mice) A/Vietnam/1203/04 (H5N1) oseltamivir  5 days 0.1 0/10 10.7
1.0 0/10 12.2
10.0 5/10 20.1
control 0/10 9.6
oseltamivir  8 days 0.1 1/10 11.6
1.0 6/10 12.1
10.0 8/10 13.0
control 0/10 11.0
Smith
ii2875 mg, current dosages approved for seasonal inﬂuenza may
need to be modiﬁed to combat effectively a potential pandemic
virus based on the highly pathogenic inﬂuenza A/H5N1 strain.
A higher dosage (e.g. 150 mg twice daily in adults) and increased
duration of therapy may be reasonable in light of the high levels
of replication of inﬂuenza A/H5N1, observations of progressive
disease despite early treatment with standard dosages in
some patients, and the apparent safety of higher dosages of
oseltamivir in patients with seasonal inﬂuenza.
2
The safety of a dosage of 150 mg twice daily given for 5 days
has been demonstrated in two randomized and controlled
studies in which 454 adult patients received this regimen for
the treatment of acute seasonal inﬂuenza infection.
50,51 In
these studies, the 150 mg regimen was shown to be as effective
as the 75 mg regimen, with no apparent effect of the increased
dosage on the incidence or severity of adverse events, most of
which were transient and gastrointestinal in nature. Favourable
tolerability at the 150 mg dose level was also reported in a
study of experimental inﬂuenza B infection,
52 a dose-ranging
study
53 and three pharmacokinetic studies.
54–56
Higher doses have also been well tolerated. One study
exposed 391 healthy volunteers to dosages of oseltamivir up
to 450 mg twice daily for 5 days.
57 In this trial, in which
dosages of 75 and 225 mg twice daily were also given,
nausea, vomiting and headache were most commonly reported,
and there was no apparent effect of oseltamivir at any dosage
on QTc intervals or other electrocardiogram (ECG) parameters.
No serious adverse events were reported. There was a
dosage-related increase in gastrointestinal adverse events, with
the majority of instances of nausea and vomiting being seen in
the two highest dosage groups. Most were of mild to moderate
severity and were transient. In other studies, oseltamivir was
well tolerated at single doses of up to 675 mg
58 and
1000 mg,
59 and twice daily doses of up to 500 mg for 7 days.
59
Given that individuals infected with inﬂuenza A/H5N1 are
usually seriously ill (often with pneumonia) and need mechan-
ical ventilation, the efﬁcacy of nasogastric administration of
oseltamivir is of considerable interest. Taylor et al.
60 investi-
gated the pharmacokinetics of nasogastrically administered
oseltamivir at a dose of 150 mg twice daily for 10 days in
three severely ill patients, two with H5N1 (including one preg-
nant female) and one with inﬂuenza A/H3N2. Treatment com-
menced on day 6 of illness or later in all patients. Virus was
cleared from two patients (one male infected with H5N1 and
one elderly female with H3N2) after 5 days of treatment
although the female subsequently died of respiratory failure.
The pregnant female also died of respiratory failure. Oseltamivir
was well absorbed and converted extensively into oseltamivir
carboxylate, with trough concentrations exceeding the IC50
(50% inhibitory concentration) for the H5N1 virus isolated
from the pregnant female by 545- to 3956-fold. Good absorp-
tion and therapeutic concentrations were also detected after
nasogastric administration of oseltamivir to a child with
inﬂuenza B-associated encephalitis.
61
Animal data show that beneﬁt might be obtained through the
use of longer courses of therapy,
47 and this approach has been
investigated in several human studies in seasonal inﬂuenza.
Inﬂuenza prophylaxis with oseltamivir in the community has
been given for up to 6 weeks in a study in children aged
1–12 years,
62 in two large studies in 1559 adults
63 and in
.500 vaccinated frail elderly persons in the residential care
setting.
64 Prophylactic dosing has been used successfully and
safely for 8 weeks in a study in 32 immunocompromised children
and young people
65 and, more recently, for 12 weeks in a
placebo-controlled study involving 477 solid organ and stem
cell transplant patients aged  1 year.
66 Oseltamivir prophylaxis
has also been given for up to 13 weeks in at-risk healthcare
workers.
67 In all reported studies, oseltamivir has been well tol-
erated and has reduced the incidence of infection substantially.
An extended duration of prophylactic dosing is of particular rel-
evance to healthcare workers in a pandemic situation, as these
personnel play a key role in managing and containing an out-
break while being exposed to the virus over extended periods.
Resistance to oseltamivir in H5N1 viruses
Most neuraminidases of H5N1 viruses appear to be susceptible to
oseltamivir. Comparison of virus isolates from Asia from 1997 to
2005 found that viral neuraminidases from strains isolated in
2004 and 2005 were 10 times more susceptible to oseltamivir
than H5N1 isolates from 1997 and 2003 and a H1N1 isolate from
2004.
68 Fifty-three of 55 strains of H5N1 virus from Australia and
South-East Asian countries analysed between 2004 and 2006
were shown to be susceptible to neuraminidase inhibitors, their
IC50 values being similar to those for H1N1 strains circulating
in this region between 2001 and 2006.
69 The remaining two
strains exhibited higher IC50 values of oseltamivir than wild-type
viruses. However, these values represented only small decreases
in susceptibility, and would not be expected to be associated
with reduced clinical efﬁcacy at recommended doses. A second
Table 2. Results of rechallenge of ferrets with a lethal dose of homologous H5N1 after earlier oseltamivir treatment; all three rechallenged ferrets
survived with no clinical signs of disease; reproduced from Govorkova et al.
37 with permission
Range of pre-challenge HI titres (3 weeks after initial
inoculation, expressed as reciprocal values)
Virus
Oseltamivir regimen used to
treat initial infection
Rechallenge virus dose
(EID50/ferret) A/Vietnam/1203/04 A/HK/213/03 A/Turkey/15/06
A/Vietnam/1203/04 25 mg/kg/day (24 h delay) 10
2 20–40 80–160 not tested
A/Turkey/15/06 10 mg/kg/day (24 h delay) 10
7 20–40 320–640 160–320
EID50, 50% egg infectious dose; HI, haemagglutinin inhibition.
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JACexample of such a natural variant was reported in Egypt, where
the N294S mutation was found in H5N1 virus isolates taken
before and after oseltamivir treatment from two infected
patients who later died.
70 This mutation reduced susceptibility
to the drug by 12–15 times. Recent data conﬁrm that the
N294S mutation, and the H274Y mutation that confers high
level resistance to oseltamivir, are rare in circulating H5N1
viruses; of 676 isolates, only 1 contained N294S and 4 contained
H274Y.
71
The available information suggests that the incidence of
selection of clinically signiﬁcant resistance during treatment of
H5N1 infection with oseltamivir is low. In a study of Indonesian
patients treated with oseltamivir for H5N1 infections, no H275Y
mutants were found in samples taken from 75 patients on
admission or taken from 25 patients during the ﬁrst 3 days of
treatment follow-up.
72 Indeed, only three cases of infection
with oseltamivir-resistant A/H5N1 viruses (all H275Y mutants)
have been reported, all in Vietnamese patients. A patient who
received oseltamivir treatment at the prevention dose (75 mg
once daily) for 4 days despite being symptomatic recovered
after a dose increase led to clearance of the virus.
9 In two
other patients, both of whom died, oseltamivir treatment was
given at the correct dose, but was started late in one case
(sixth day of illness).
73 In all three cases, resistant virus was iso-
lated after treatment had started.
Combination chemotherapy
For other viral infections, combination chemotherapy has been
successfully used to improve efﬁcacy and/or reduce the emer-
gence of drug resistance. By combining oseltamivir with an anti-
viral that has an alternative mechanism of action, similar
advantages might be obtained. Amantadine and rimantadine
are established antiviral agents for inﬂuenza that have a mech-
anism of action different from that of oseltamivir, and work by
inhibiting the M2 ion channel. Recent publications suggest that
combination therapy with either agent and oseltamivir could
be advantageous over monotherapy.
74–79 Addition of ribavirin
to this combination has also been investigated.
80
Clinical pharmacokinetics
In a recent study, Morrison et al.
74 investigated the pharmacoki-
netic proﬁles of amantadine and oseltamivir in healthy human
volunteers. Seventeen subjects took part in the study, and
each received amantadine and oseltamivir as monotherapy
and as combination chemotherapy, with an appropriate
wash-out between each regimen. Compared with monotherapy,
neither drug had any clinically signiﬁcant effect on the
pharmacokinetics of the other when co-administered. There
was also no increase in adverse events for the combination
versus oseltamivir or amantadine monotherapy. The authors
concluded that combination chemotherapy with oseltamivir
and amantadine appeared safe and was without pharmacoki-
netic consequences.
74
Pre-clinical efﬁcacy
The activity of the oseltamivir/amantadine combination has
been studied in vitro and in mice infected with seasonal and
avian inﬂuenza viruses.
75,77In MDCK cells infected with inﬂuenza
A/Hong Kong/1/68 (H3N2) or inﬂuenza A/PR/8/34 (H1N1), a com-
bination of oseltamivir and amantadine reduced viral replication
to a greater extent than that seen with either antiviral alone.
75 In
mice infected with lethal doses of the same mouse-adapted
H1N1 or H3N2 strains, oseltamivir or amantadine monotherapy
conferred 50%–60% survival, while complete protection was
achieved with an oseltamivir/amantadine combination in which
oseltamivir was administered at a lower dose than that used
for monotherapy.
75 The combination was also effective against
amantadine-resistant H1N1. In a further study, mice were
given preventative doses of oseltamivir and amantadine, either
separately or in combination.
77 A lethal dose of amantadine-
susceptible or amantadine-resistant inﬂuenza A/Vietnam/1203/
04 (H5N1) was then administered. Combination chemotherapy
provided 60%–90% greater protection than monotherapy,
depending on the amantadine dose. The efﬁcacy of the combi-
nation against amantadine-resistant H5N1 was comparable to
that with oseltamivir alone. Oseltamivir monotherapy produced
dose-dependent protection against both amantadine-
susceptible and amantadine-resistant viruses.
Combination therapy with oseltamivir and rimantadine has
also been studied in vitro and in vivo. In MDCK cells infected
with inﬂuenza A/New Caledonia/20/99 (H1N1) or A/Panama/
2007/99 (H3N2), amantadine plus rimantadine effectively
reduced virus yields and was more effective than either agent
alone.
78 Combination chemotherapy also provided greater pro-
tection against lethal infection and prolonged survival versus
monotherapy in mice infected with inﬂuenza A/Aichi/2/68
(H3N2).
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Resistance
In addition to improved efﬁcacy, combination chemotherapy
with oseltamivir and amantadine or rimantadine could also
decrease the emergence of resistant variants. Ilyushina et al.
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investigated this property in MDCK cells infected with human
seasonal inﬂuenza A/Nanchang/1/99 (H1N1) and A/Panama/
2007/99 (H3N2) or avian inﬂuenza A/Hong Kong/156/97
(H5N1). Yields of all three viruses were signiﬁcantly reduced
when the cells were treated with a combination of oseltamivir
and amantadine. While mutations associated with reduced anti-
viral susceptibility were noted with oseltamivir and amantadine
monotherapy after repeated passages in MDCK cells, no
mutations of the haemagglutinin, neuraminidase or M2 proteins
were detected when the medications were used in combination.
Ongoing studies
To address the issues surrounding dosing requirements in a
future pandemic, Roche is developing a mathematical model
based on viral kinetics in the presence and absence of oseltamivir
therapy to facilitate rapid prediction of appropriate regimens.
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Roche is also supporting an open-label clinical study that will
compare the efﬁcacy and safety of oseltamivir monotherapy
with oseltamivir/amantadine combination chemotherapy for
5 days in adults aged between 18 and 65 years with conﬁrmed
inﬂuenza A infections (clinicaltrials.gov reference NCT00830323).
As published evidence on other combination chemotherapies is
currently lacking, the study will also investigate the activity of
Smith
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neuraminidase inhibitor. The study, which is being conducted in
France, aims to recruit 60 subjects. A further randomized, double-
blind, placebo-controlled study in France (clinicaltrials.gov refer-
ence NCT00799760) will compare the efﬁcacy and safety of com-
bination therapy with oseltamivir and zanamivir versus oseltamivir
and zanamivir monotherapy (plus placebo to maintain the blind)
in patients aged  12 years. Each drug will be taken at the stan-
dard dose for 5 days, whether alone or in combination, and
patients will be stratiﬁed by time to treatment start from
symptom onset (,36 h and  36 h). The target recruitment is
300 patients per group. The results of these studies should
further inform inﬂuenza pandemic planning strategies.
Conclusions
Avian inﬂuenza A viruses continue to cause disease outbreaks in
humans. Animal models of avian infection demonstrate that
oseltamivir is active against H5, H7 and H9 viruses when given
as treatment or prophylaxis; outcomes are inﬂuenced by the
virulence of the viral strain, dosage regimen and treatment
delay. Observational data on oseltamivir treatment in human
disease suggest its usefulness for reducing the frequency of
H5-associated mortality, while resistance has only rarely
emerged during treatment. On this basis and the systemic
action of the drug, the WHO recommend oseltamivir as the
primary intervention for the treatment and prevention of
human H5N1 disease. Modiﬁed regimens and antiviral combi-
nations may further improve the control of viral replication in
these patients.
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